De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Biodesix Beheer

Beheer criteriumcontroles 3/4

De CEO Biodesix's is Scott Hutton, benoemd in Jan2020, heeft een ambtstermijn van 4.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.29M, bestaande uit 22.5% salaris en 77.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.36% van de aandelen van het bedrijf, ter waarde $ 922.70K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.7 jaar en 4.8 jaar.

Belangrijke informatie

Scott Hutton

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris	22.5%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	4.7yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Analyse CEO-vergoeding

Hoe is Scott Hutton's beloning veranderd ten opzichte van Biodesix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$2m	US$515k	-US$52m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$3m	US$515k	-US$65m
Sep 30 2022	n/a	n/a	-US$58m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$5m	US$490k	-US$43m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$364k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$34m
Mar 31 2020	n/a	n/a	-US$33m
Dec 31 2019	US$337k	US$298k	-US$31m

Compensatie versus markt: De totale vergoeding ($USD 2.29M ) Scott } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.49M ).

Compensatie versus inkomsten: De vergoeding van Scott is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Scott Hutton (52 yo)

4.8yrs

Tenure

US$2,290,546

Compensatie

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Hutton	President	4.8yrs	US$2.29m	0.36% $ 876.0k
Robin Cowie	CFO, Secretary & Treasurer	7.5yrs	US$844.37k	0.13% $ 323.1k
Kieran O'Kane	Chief Commercial Officer	6.7yrs	US$672.62k	0.062% $ 151.5k
Heinrich Röder	Founder & CTO	no data	geen gegevens	geen gegevens
Jessica Olbricht	Senior Director of Human Resources	less than a year	geen gegevens	geen gegevens
Gary Pestano	Chief Development Officer	6yrs	geen gegevens	0.087% $ 213.1k
Bobbi Coffin	Chief Growth Officer	4.6yrs	geen gegevens	geen gegevens
James Jett	Co-Chief Medical Officer	no data	geen gegevens	geen gegevens
Steven Springmeyer	Co-Chief Medical Officer	4.4yrs	geen gegevens	geen gegevens
Christopher Vazquez	VP & Controller	3.7yrs	geen gegevens	0.0077% $ 18.9k

4.7yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BDSX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Hutton	President	4.8yrs	US$2.29m	0.36% $ 876.0k
John Patience	Independent Chairman	16.3yrs	US$187.58k	5.03% $ 12.3m
Jack Schuler	Independent Director	16.3yrs	US$187.58k	21.21% $ 52.0m
Hany Massarany	Independent Director	4.3yrs	US$201.47k	0.22% $ 531.7k
Lair Kennedy	Independent Director	1.8yrs	US$465.10k	17.46% $ 42.8m
Paul A. Bunn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Matthew Strobeck	Independent Director	12.8yrs	US$196.84k	2.11% $ 5.2m
John Kayyem	Independent Director	2.8yrs	US$187.58k	0.25% $ 604.2k
David Carbone	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Craig Whitehouse	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jean Franchi	Independent Director	4.5yrs	US$206.10k	0.056% $ 138.2k
Charles Watts	Independent Director	5.3yrs	US$187.58k	0.26% $ 633.8k

4.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BDSX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Biodesix Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Biodesix, Inc., Annual General Meeting, May 21, 2024

President notifies of intention to sell stock

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Independent Director recently bought US$125k worth of stock

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%